T. Rowe Price Associates’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.22M | Buy |
53,977
+1,995
| +4% | +$44.3K | ﹤0.01% | 2053 |
|
|
2025
Q4 | $1.35M | Buy |
51,982
+2,001
| +4% | +$47.6K | ﹤0.01% | 1954 |
|
|
2025
Q3 | $1.29M | Buy |
49,981
+2,071
| +4% | +$50.9K | ﹤0.01% | 1947 |
|
|
2025
Q2 | $1.15M | Buy |
47,910
+2,916
| +6% | +$73.5K | ﹤0.01% | 1928 |
|
|
2025
Q1 | $1.12M | Buy |
44,994
+3,688
| +9% | +$88.3K | ﹤0.01% | 1900 |
|
|
2024
Q4 | $779K | Sell |
41,306
-9,409
| -19% | -$165K | ﹤0.01% | 2079 |
|
|
2024
Q3 | $764K | Sell |
50,715
-198,429
| -80% | -$3.39M | ﹤0.01% | 2076 |
|
|
2024
Q2 | $7.13M | Sell |
249,144
-82,876
| -25% | -$2.36M | ﹤0.01% | 1162 |
|
|
2024
Q1 | $9.7M | Sell |
332,020
-71,733
| -18% | -$2.2M | ﹤0.01% | 1116 |
|
|
2023
Q4 | $13.6M | Sell |
403,753
-5,236
| -1% | -$153K | ﹤0.01% | 1037 |
|
|
2023
Q3 | $12.5M | Buy |
408,989
+1,447
| +0.4% | +$52.2K | ﹤0.01% | 1024 |
|
|
2023
Q2 | $16.3M | Buy |
407,542
+1,256
| +0.3% | +$51.9K | ﹤0.01% | 988 |
|
|
2023
Q1 | $16.6M | Buy |
406,286
+2,164
| +0.5% | +$86.1K | ﹤0.01% | 967 |
|
|
2022
Q4 | $15.6M | Buy |
404,122
+11,048
| +3% | +$538K | ﹤0.01% | 974 |
|
|
2022
Q3 | $20.9M | Buy |
393,074
+4,384
| +1% | +$244K | ﹤0.01% | 887 |
|
|
2022
Q2 | $22.7M | Buy |
388,690
+10,925
| +3% | +$716K | ﹤0.01% | 1132 |
|
|
2022
Q1 | $28.8M | Buy |
377,765
+2,304
| +0.6% | +$154K | ﹤0.01% | 1135 |
|
|
2021
Q4 | $22.6M | Buy |
375,461
+3,873
| +1% | +$214K | ﹤0.01% | 1258 |
|
|
2021
Q3 | $20.8M | Sell |
371,588
-2,064
| -0.6% | -$119K | ﹤0.01% | 1287 |
|
|
2021
Q2 | $22.7M | Buy |
373,652
+9,689
| +3% | +$613K | ﹤0.01% | 1270 |
|
|
2021
Q1 | $25.5M | Sell |
363,963
-5,326
| -1% | -$380K | ﹤0.01% | 1215 |
|
|
2020
Q4 | $22.1M | Sell |
369,289
-2,932
| -0.8% | -$172K | ﹤0.01% | 1205 |
|
|
2020
Q3 | $22.4M | Buy |
372,221
+514
| +0.1% | +$29.9K | ﹤0.01% | 1123 |
|
|
2020
Q2 | $19.5M | Sell |
371,707
-45,362
| -11% | -$1.9M | ﹤0.01% | 1152 |
|
|
2020
Q1 | $14M | Sell |
417,069
-2,052
| -0.5% | -$85.2K | ﹤0.01% | 1167 |
|
|
2019
Q4 | $19M | Buy |
419,121
+9,801
| +2% | +$416K | ﹤0.01% | 1200 |
|
|
2019
Q3 | $15.6M | Buy |
409,320
+4,947
| +1% | +$197K | ﹤0.01% | 1219 |
|
|
2019
Q2 | $17.6M | Buy |
404,373
+37,443
| +10% | +$1.59M | ﹤0.01% | 1213 |
|
|
2019
Q1 | $14M | Sell |
366,930
-717,082
| -66% | -$28M | ﹤0.01% | 1263 |
|
|
2018
Q4 | $46.6M | Sell |
1,084,012
-200,751
| -16% | -$9.37M | 0.01% | 845 |
|
|
2018
Q3 | $63.1M | Sell |
1,284,763
-379,791
| -23% | -$16.4M | 0.01% | 823 |
|
|
2018
Q2 | $53.3M | Sell |
1,664,554
-141,714
| -8% | -$4.89M | 0.01% | 873 |
|
|
2018
Q1 | $56.3M | Sell |
1,806,268
-10,798
| -0.6% | -$384K | 0.01% | 826 |
|
|
2017
Q4 | $82.9M | Buy |
1,817,066
+27,014
| +2% | +$1.07M | 0.01% | 705 |
|
|
2017
Q3 | $67.2M | Sell |
1,790,052
-266,740
| -13% | -$10.7M | 0.01% | 743 |
|
|
2017
Q2 | $98.1M | Sell |
2,056,792
-383,488
| -16% | -$17.8M | 0.02% | 611 |
|
|
2017
Q1 | $111M | Sell |
2,440,280
-139,221
| -5% | -$6.02M | 0.02% | 570 |
|
|
2016
Q4 | $83.3M | Sell |
2,579,501
-798,090
| -24% | -$26.6M | 0.02% | 655 |
|
|
2016
Q3 | $116M | Sell |
3,377,591
-1,054,152
| -24% | -$41.3M | 0.02% | 540 |
|
|
2016
Q2 | $149M | Buy |
4,431,743
+298,369
| +7% | +$14.7M | 0.03% | 471 |
|
|
2016
Q1 | $219M | Buy |
4,133,374
+90,079
| +2% | +$5.27M | 0.05% | 378 |
|
|
2015
Q4 | $310M | Buy |
4,043,295
+126,925
| +3% | +$7.19M | 0.07% | 303 |
|
|
2015
Q3 | $161M | Buy |
3,916,370
+50,543
| +1% | +$3.1M | 0.04% | 457 |
|
|
2015
Q2 | $273M | Sell |
3,865,827
-450,394
| -10% | -$35.5M | 0.06% | 367 |
|
|
2015
Q1 | $383M | Sell |
4,316,221
-61,430
| -1% | -$6.23M | 0.08% | 289 |
|
|
2014
Q4 | $388M | Sell |
4,377,651
-752,614
| -15% | -$71.2M | 0.08% | 282 |
|
|
2014
Q3 | $497M | Buy |
5,130,265
+403,539
| +9% | +$39.3M | 0.11% | 222 |
|
|
2014
Q2 | $434M | Buy |
4,726,726
+79,630
| +2% | +$6.06M | 0.09% | 255 |
|
|
2014
Q1 | $325M | Sell |
4,647,096
-119,171
| -3% | -$8.11M | 0.07% | 316 |
|
|
2013
Q4 | $274M | Sell |
4,766,267
-130,563
| -3% | -$6.87M | 0.06% | 355 |
|
|
2013
Q3 | $235M | Sell |
4,896,830
-1,067,873
| -18% | -$38.9M | 0.06% | 367 |
|
|
2013
Q2 | $173M | Buy |
+5,964,703
| New | +$173M | 0.05% | 427 |
|
Other funds holding PCRX
DPCM
VPM
VCM
T. Rowe Price Associates's PCRX Position: Q1 2026 in Review
T. Rowe Price Associates increased its Pacira BioSciences (PCRX) stake by 3.8% in Q1 2026, buying an estimated $44.3K and bringing the position to 53,977 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #2053.
T. Rowe Price Associates first reported a position in PCRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $497M in Q3 2014. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.
- T. Rowe Price Associates held 53,977 shares of Pacira BioSciences worth $1.22M as of Q1 2026.
- T. Rowe Price Associates bought 1,995 Pacira BioSciences shares in Q1 2026, an estimated $44.3K.
- Pacira BioSciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2053 holding.
- T. Rowe Price Associates first reported a position in Pacira BioSciences in Q2 2013 and has held it in 52 quarters since.
- T. Rowe Price Associates's Pacira BioSciences position peaked at $497M in Q3 2014.
- 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.